IMMUNISBIO Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
IMMUNISBIO Co., Ltd. - overview
Established
2016
Location
Incheon, -, South Korea
Primary Industry
Biotechnology
About
Based in Incheon, South Korea, and founded in 2016, IMMUNISBIO Co. , Ltd. operates as a cell therapy development company that is focused on the development of immune cell therapy such as immune cell therapy, functional cosmetics, culture automation, and technology export, with the goal of curing cancer-related diseases. In February 2021, IMMUNISBIO Co.
, Ltd. raised KRW 4. 5 billion in series B funding led by new investor Samho Green Investment. New investors Sejong Venture Partners and Honest Ventures also participated in this round.
Current Investors
Samho Green Investment, Sejong Venture Partners, Honest Ventures
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Aesthetic Medicine, Alternative Medicine, Oncology/Cancer Treatment
Website
www.immunisbio.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
IMMUNISBIO Co., Ltd. - financials
| Fiscal Year Ended | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|
| Revenue (USD) | 981,964,990 | 1,227,203,547 | 1,538,240,757 | 1,569,195,729 | - | - | - |
| % Revenue Growth (YoY) | - | 25.0% | 25.3% | 2.0% | - | - | - |
| EBITDA (USD) | (1,730,113,942) | (1,585,890,893) | (3,353,001,850) | (2,318,658,484) | - | - | - |
| Operating Income (USD) | (1,965,591,755) | (1,864,864,407) | (3,661,308,120) | (2,580,669,980) | - | - | - |
| Operating Margin | (200.2%) | (152.0%) | (238.0%) | (164.5%) | - | - | - |
| % EBITDA Margin | (176.2%) | (129.2%) | (218.0%) | (147.8%) | - | - | - |
| NET Income (USD) | (1,960,979,857) | (8,691,854,167) | (5,293,679,212) | (1,887,896,703) | - | - | - |
| % Net Margin | (199.7%) | (708.3%) | (344.1%) | (120.3%) | - | - | - |
IMMUNISBIO Co., Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Secondary Stock Purchase | Completed | IMMUNISBIO Co., Ltd. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.